pathological myopia
Conditions
Interventions
test group:Intravitreal injection of Conbercept + Jiajian Zhujingfang Granules
control group:Intravitreal injection of Conbercept +placebo granules
Sponsors
Eye Hospital China of Academy Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: ?At least one case meeting the above diagnostic criteria; ? TCM syndrome type is liver and kidney deficiency type; ?Age 18-60 years old (excluding 18 years old and 60 years old); ? Not receiving fundus laser or intrabulbar injection of anti-VEGF drugs within 3 months; ? The refractive interstitium is basically clear and does not hinder the fundus examination or fundus fluoroscopy examination; ? The subjects can understand and are willing to accept the treatment and re-examination according to the experimental plan; ? Sign the informed consent.
Exclusion criteria
Exclusion criteria: ?Combined age-related macular degeneration, glaucoma, diabetic retinopathy, retinal artery occlusion, retinal vein occlusion, idiopathic or secondary epimacular membrane, choroidopathy, optic nerve disease (optic neuritis, optic atrophy), macular hole, etc. eye disease that affects the outcome; ?The test eye has undergone intraocular surgery within 3 months; ? Those who have participated in clinical trials of any drug or medical device within 3 months before the trial, or those who plan to participate in other clinical trials during this trial; ? Those who are allergic to sodium fluorescein; ? Patients with moderate or severe liver dysfunction, or patients with severe heart, lung, kidney dysfunction, hematopoietic system diseases and mental illness; ? Those who cannot cooperate with the inspection process; ?Can not insist on tracking fundus examination; ? Pregnant and lactating patients; ? Participating in other clinical investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| best corrected visual acuity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence rate;TCM symptom score;macular hemorrhage absorption;retinal thickness;Choroidal neovascular leakage; | — |
Countries
China
Contacts
Public ContactZe-Feng Kang
Outcome results
None listed